Fertility-Sparing Surgery for Endometrial Cancer
(FETCH Trial)
Trial Summary
The trial does not specify if you need to stop taking your current medications. However, it requires that you have already tried anti-hormone therapy, like high-dose progestin, for at least 6 months before participating.
Research shows that hysteroscopic endometrial resection can be effective in conservatively treating early endometrial cancer in women who want to preserve their fertility. It has been used successfully in some cases to manage early-stage endometrial cancer, allowing women to achieve pregnancy with assisted reproductive technology.
12345Hysteroscopic surgery is generally considered safe with rare complications, but as procedures become more complex, complications like bleeding, uterine perforation, and fluid overload can occur. Awareness and prevention of these issues help ensure patient safety.
26789Hysteroscopic uterine resection is unique because it allows for the conservative management of early-stage endometrial cancer while preserving fertility, unlike the standard treatment of hysterectomy, which results in infertility. This approach combines surgery with hormone therapy and can lead to a faster return to fertility and shorter remission times.
1241011Eligibility Criteria
This trial is for women under 40 with early-stage endometrial cancer or atypical hyperplasia who haven't improved with hormone therapy and want to keep their fertility. They should have less than a third of the uterus affected, no severe health issues that could complicate surgery, and a reasonable chance to conceive as assessed by a fertility specialist.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo hysteroscopic endomyometrial resection to treat atypical hyperplasia or Grade I endometrial cancer
Follow-up
Participants are monitored for local disease control and complications post-resection
Long-term Follow-up
Participants are monitored for distant disease control and conception rates
Participant Groups
Hysteroscopic uterine resection is already approved in European Union, United States, Canada, Australia for the following indications:
- Abnormal uterine bleeding
- Endometrial hyperplasia
- Endometrial cancer
- Fibroids
- Polyps
- Uterine adhesions
- Abnormal uterine bleeding
- Endometrial hyperplasia
- Endometrial cancer
- Fibroids
- Polyps
- Uterine adhesions
- Sterilization
- Abnormal uterine bleeding
- Endometrial hyperplasia
- Endometrial cancer
- Fibroids
- Polyps
- Uterine adhesions
- Abnormal uterine bleeding
- Endometrial hyperplasia
- Endometrial cancer
- Fibroids
- Polyps
- Uterine adhesions